Blood pressure lowering efficacy of drugs inhibiting the renin-angiotensin system as second-line therapy for primary hypertension

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 10, 2020, Pages

  Luo, Hai Chang ^a   Yang, Zi Xuan ^b   Zhang, Wei Feng ^a   Tang, Wen Lu ^a   Li, Liang Jin ^a   Chen, Jenny MH ^c   Heran, Balraj S ^c   Wright, James M ^c  

^a FUDAN UNIVERSITY   (China)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALACEPRIL; ALFUZOSIN; ALISKIREN; ALPRENOLOL; ALTIOPRIL; AMILORIDE; AMLODIPINE; AMOSULALOL; AMRINONE; ARANIDIPINE; AROTINOLOL; ATENOLOL; AZILSARTAN; AZOSEMIDE; BEFUNOLOL; BENAZEPRIL; BENCYCLANE; BENDROFLUMETHIAZIDE; BENIDIPINE; BEPRIDIL; BETAXOLOL; BEVANTOLOL; BISOPROLOL; BOPINDOLOL; BUCINDOLOL; BUCUMOLOL; BUFETOLOL; BUFURALOL; BUMETANIDE; BUNITROLOL; BUTIZIDE; BUTOFILOLOL; CANDESARTAN; CAPTOPRIL; CARAZOLOL; CARTEOLOL; CARVEDILOL; CELIPROLOL; CERANAPRIL; CETAMOLOL; CHLOROTHIAZIDE; CHLORTALIDONE; CICLETANINE; CILAZAPRIL; CILNIDIPINE; CINNARIZINE; CIPROKIREN; CLENTIAZEM; CLONIDINE; CLOPAMIDE; CLORANOLOL; CLOREXOLONE; CYCLOPENTHIAZIDE; DELAPRIL; DILTIAZEM; EFONIDIPINE; ENALAPRIL; ENALAPRILAT; EPANOLOL; EPICAPTOPRIL; EPLERENONE; EPROSARTAN; ESMOLOL; ETACRYNIC ACID; ETAFENONE; ETOZOLIN; FANTOFARONE; FASIDOTRIL; FELODIPINE; FENDILINE; FLUNARIZINE; FOROXYMITHINE; FOSINOPRIL; FUROSEMIDE; GALLOPAMIL; GEMOPATRILAT; GUANABENZ; GUANFACINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; IMIDAPRIL; INDACRINONE; INDAPAMIDE; INDENOLOL; IRBESARTAN; ISRADIPINE; LABETALOL; LACIDIPINE; LERCANIDIPINE; LEVOBUNOLOL; LIBENZAPRIL; LIDOFLAZINE; LISINOPRIL; LOMERIZINE; LOOP DIURETIC AGENT; LOSARTAN; MANIDIPINE; MEFRUSIDE; MEPINDOLOL; MEPIRODIPINE; METHYCLOTHIAZIDE; METHYLDOPA; METOLAZONE; METOPROLOL; MIBEFRADIL; MOEXIPRIL; MOPROLOL; MOXONIDINE; MUZOLIMINE; NADOLOL; NEBIVOLOL; NICARDIPINE; NIFEDIPINE; NIFENALOL; NIGULDIPINE; NILVADIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; OLMESARTAN; OMAPATRILAT; OXPRENOLOL; OZOLINONE; PAFENOLOL; PENBUTOLOL; PENTOPRIL; PERHEXILINE; PERINDOPRIL; PINDOLOL; PIRETANIDE; POLYTHIAZIDE; PRACTOLOL; PRENYLAMINE; PRONETALOL; PROPRANOLOL; QUINAPRIL; QUINETHAZONE; RAMIPRIL; REMIKIREN; RENIN INHIBITOR; RENTIAPRIL; RESERPINE; RILMENIDINE; SARTAN DERIVATIVE; SEMOTIADIL; SOTALOL; SPIRAPRIL; SPIRONOLACTONE; TALINOLOL; TELMISARTAN; TEMOCAPRIL; TEPROTIDE; TERLAKIREN; TERODILINE; TERTATOLOL; THIAZIDE DIURETIC AGENT; TIAMIZIDE; TIAPAMIL; TIENILIC ACID; TILISOLOL; TIMOLOL; TOLIPROLOL; TORASEMIDE; TRANDOLAPRIL; TRIAMTERENE; TRICHLORMETHIAZIDE; TRIPAMIDE; VALSARTAN; VERAPAMIL; XIBENOLOL; XIPAMIDE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; HEART RATE; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 85103052443     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007188.pub2     Document Type: Article

References (20)

1. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. Journal of Hypertension 1994;12(9):1053-60.
2. Byrd JB, Zeng C, Tavel HM, Magid DJ, O'Connor PJ, Margolis KL, et al. Combination therapy as initial treatment for newly diagnosed hypertension. American Heart Journal 2011;162(2):340-6.
3. Chen JMH, Heran BS, Wright JM. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No: CD007187. [DOI: 10.1002/14651858.CD007187.pub2]
4. Chen JMH, Heran BS, Perez MI, Wright JM. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD007185. [DOI: 10.1002/14651858.CD007185.pub2]
5. Williams B, Mancia G, Spiering W, Agabiti RE, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018;39(33):3021-104.
6. Garjón J, Saiz LC, Azparren A, Gaminde I, Ariz MJ, Erviti J. First-line combination therapy versus first-line monotherapy for primary hypertension. Cochrane Database of Systematic Reviews 2020, Issue 2. Art. No: CD010316. [DOI: 10.1002/14651858.CD010316.pub3]
7. McMaster University (developed by Evidence Prime) GRADEpro GDT. McMaster University (developed by Evidence Prime), Version accessed 21 September 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.
8. Gradman AH, Basile JN, Carter BL, et al, American Society of Hypertension Writing Group. Combination therapy in hypertension. Journal of the American Society of Hypertension 2010;4(1):42-50.
9. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
10. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
11. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-35.
12. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. American Journal of Medicine 2011;124(2):128-35.
13. Musini VM, Wright JM. Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials. PLoS ONE 2009;4(5):e5673. [DOI: 10.1371/journal.pone.0005673]
14. Musini VM, Lawrence KAK, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]
15. Redón J, Coca A, Lázaro P, Aguilar MD, Cabañas M, Gil N, et al. Factors associated with therapeutic inertia in hypertension: validation of a predictive model. Journal of Hypertension 2010;28(8):1770-7.
16. Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Cochrane, 2020.
17. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. European Heart Journal 2011;32(20):2499-506.
18. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62(3):443-62.
19. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. American Journal of Medicine 2009;122(3):290-300.
20. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-7.